HNGE vs RDNT: How Hinge Health and RadNet Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: HNGE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and RDNT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and RDNT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

RadNet operates a network of several hundred outpatient imaging centers, mostly clustered in dense markets such as California, the Northeast, Maryland and Florida, and many of them are run in joint venture with local hospitals and health systems. The centers perform MRI, CT, PET, mammography, ultrasound and X-ray, and revenue comes primarily from commercial insurers, Medicare and Medicaid, plus a growing slice of self-pay screening. A second reporting segment, Digital Health, houses DeepHealth, the company's radiology AI and software business, which sells clinical AI tools, imaging workflow software and an enhanced breast cancer detection add-on that patients often pay for directly. The 2026 acquisition of Gleamer widened that segment's product range and installed base internationally.

Full RDNT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
• RDNT drivers: The site-of-care shift out of hospitals; Digital Health and the DeepHealth stack.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas. For RDNT, reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income.

Pick HNGE if you believe its drivers more; RDNT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and RDNT guides.

HNGE. Hinge Health's valuation reflects the digital health growth premium, the demonstrated category leadership in MSK, and the path-to-profitability story. As a recent IPO, valuation is sensitive to broader digital health sector sentiment and to quarterly progression toward profitability.

RDNT. At roughly $5.0B of market value on roughly $1.9B of trailing revenue, RDNT trades near 2.6 times sales for a business whose GAAP bottom line is around breakeven, so the multiple is being carried by adjusted EBITDA, free cash flow growth and the Digital Health segment rather than by earnings. Management's 2026 guidance calls for revenue growth of roughly 17% to 19% and adjusted EBITDA growth of roughly 18% to 22%, which is the frame most of the sell side uses. Second quarter 2026 results were scheduled for August 10, 2026, so the figures above reflect Q1 2026 and the most recent trailing data available before that report.

Headline figures (approximate, early 2026): HNGE shows revenue (ttm) ~$400 million (estimated, post-IPO disclosure), operating margin Approaching breakeven; varies by quarter, net income (ttm) Modest GAAP loss; non-GAAP near breakeven, eps (ttm) Near zero; RDNT shows market cap ~$5.0B (late July 2026), revenue (ttm) ~$1.9B, q1 2026 revenue ~$575.6M, up ~22% year over year, q1 2026 adjusted ebitda ~$63.3M.

HNGE and RDNT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HNGE and RDNT exposure against your real portfolio. It is not an investment adviser.